Robert T. O'Donnell, M.D., Ph.D. 
Clinical/Research Interests
Title:
Specialty:
Center/Program Affiliation:
Address:
4501 X St.
Sacramento, CA 95817
Phone:
Education:
Maywood , Illinois
M.D. 1987
University of Illinois at Chicago
Chicago, Illinois
Ph.D. 1983
Loyola University
Chicago, Illinois
B.S. 1977
Internships:
Sacramento, CA
1988
Residency:
Sacramento, California
1987-90
Internal Medicine
Fellowships:
Sacramento, California
1990-93
Hematology and Oncology
Board Certifications:
American Board of Internal Medicine, Medical Oncology, 2002
American Board of Internal Medicine, Medical Oncology, 1994
American Board of Internal Medicine, 1990
Professional Memberships:
Honors and Awards:
U.S. Patent 62,180,089: "Avemar and Purified Low Molecular Weight Avemar Proteins for the Treatment of Non-Hodgkin's Lymphoma: Joseph Tuscano, MD and Robert O'Donnell, MD, PhD, 2010
U.S. Patent 6,217,871 "Antigenic Epitopes with Lym-1 Reactivity and Uses Thereof": Larry Rose, PhD, Claude Meares, PhD and Robert o"Donnell MD, PhD, 2001
Bank of America Giannini Foundation Medical Research Fellowship, 1992-93
American Cancer Society Clinical Fellowship, 1990
Acting Chief Resident, UC Davis Medical Center (1 month), 1988, 1989
University of Illinois Research and Teaching Assistantships, 1984-87
University of Illinois Graduate College Fellowship, 1983
Illinois State Scholarship, 1973-77
Loyola University of Chicago Merit Scholarship, 1973-77
Select Recent Publications:
Tuscano JM, YP Ma, SM Martin, J Kato, RT O'Donnell. The Bs20x22 Anti-CD20-CD22 Bispecific Antibody has more Lymphomacidal Activity than do the Parent Monoclonal Antibodies Alone.. Cancer Immunol. Immunother., 60: 771-780.
Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res, 16(10): 2760-8.
2009 O'Donnell RT, YP Ma, HC McKnight, D Pearson, JM Tuscano. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol lmmunother. 58(12):2051-2058.
2009 O'Donnell RT, SM Martin, YP Ma, WC Zamboni, JM Tuscano. Development and characterization of CD22-targeted pegylated liposomal doxorubicin (IL-PLD). Invest New Drugs. In press.
2009 O'Donnell RT, D Pearson, HC McKnight, YP Ma, JM Tuscano. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother. Mar 18. [Epub ahead of print]
2009 O'Donnell RT, D Pearson, HC McKnight, YP Ma, JM Tuscano. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-Hodgkin's lymphoma cells. Leuk Res. Feb 21. [Epub ahead of print]
2009 Martin SM, RT O'Donnell, DL Kukis, C Abbey, H McKnight, JL Sutcliffe, JM Tuscano. Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin lymphoma xenografts. Mol Imaging BioI. 11(2):79-87.
2008 Pearson DP, RT O'Donnell, K Lam, JM Tuscano. CD22-binding peptides derived from anti-CD22 ligand blocking antibodies retain the targeting and cell killing properties of the parent antibodies and may serve as a drug delivery vehicle. International Journal of Peptide Research and Therapeutics, 14:237-246.
2007 Schillaci O, GL DeNardo, SJ DeNardo, DS Goldstein, LA Kroger, RT O'Donnell, KR Lamborn. Effect of anti-lymphoma antibody, 131 I-Lym-1 on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm, 22(4):521-30.
2007 Semrad TJ, RT O'Donnell, T Wun, H Chew, D Harvey, H Zhou, RH White. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106(4):601-608.
